Low-dose SC cohort (n = 39) | High-dose IV cohort (n = 52) | All patients (n = 91) | ||||
---|---|---|---|---|---|---|
Placebo (n = 13) | Crenezumab (n = 26) | Placebo (n = 16) | Crenezumab (n = 36) | Placebo (n = 29) | Crenezumab (n = 62) | |
Patients with ≥ 1 AE | 13 (100) | 26 (100) | 15 (93.8) | 32 (88.9) | 28 (96.6) | 58 (93.5) |
Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (5.6)* | 0 (0.0) | 2 (3.2)* |
SAEs | 1 (7.7) | 3 (11.5) | 3 (18.8) | 6 (16.7) | 4 (13.8) | 9 (14.5) |
AEs of grade ≥ 3 | 1 (7.7) | 4 (15.4) | 4 (25.0) | 7 (19.4) | 5 (17.2) | 11 (17.7) |
Pneumonia | 0 (0.0) | 1 (3.8) | 0 (0.0) | 1 (2.8) | 0 (0.0) | 2 (3.2) |
Most frequent AEs | ||||||
Back pain | 2 (15.4) | 5 (19.2) | 2 (12.5) | 5 (13.9) | 4 (13.8) | 10 (16.1) |
Upper respiratory tract infection | 0 (0.0) | 7 (26.9) | 2 (12.5) | 4 (11.1) | 2 (6.9) | 11 (17.7) |
Anxiety | 0 (0.0) | 9 (34.6) | 0 (0.0) | 3 (8.3) | 0 (0.0) | 12 (19.4) |
Nasopharyngitis | 4 (30.8) | 4 (15.4) | 13 (18.8) | 1 (2.8) | 7 (24.1) | 5 (8.1) |
Depression | 2 (15.4) | 5 (19.2) | 2 (12.5) | 2 (5.6) | 4 (13.8) | 7 (11.3) |